Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy

Nimisha Sulejmani,1 Syed-Mohammed Jafri2 1Department of Pharmacy, Henry Ford Hospital, Detroit, MI, USA; 2Division of Gastroenterology, Henry Ford Hospital, Detroit, MI, USA Abstract: Chronic hepatitis C virus (HCV) infection impacts approximately 71 million people and approximately 400,000 deaths a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sulejmani N, Jafri SM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	hepatitis c virus grazoprevir elbasvir NS3 NS4 NS5A protease inhibitors Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/b99cf70ffb03438d84369306678c807b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b99cf70ffb03438d84369306678c807b
record_format	dspace
spelling	oai:doaj.org-article:b99cf70ffb03438d84369306678c807b2021-12-02T05:16:55ZGrazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy1179-1535https://doaj.org/article/b99cf70ffb03438d84369306678c807b2018-05-01T00:00:00Zhttps://www.dovepress.com/grazoprevirelbasvir-for-the-treatment-of-adults-with-chronic-hepatitis-peer-reviewed-article-HMERhttps://doaj.org/toc/1179-1535Nimisha Sulejmani,1 Syed-Mohammed Jafri2 1Department of Pharmacy, Henry Ford Hospital, Detroit, MI, USA; 2Division of Gastroenterology, Henry Ford Hospital, Detroit, MI, USA Abstract: Chronic hepatitis C virus (HCV) infection impacts approximately 71 million people and approximately 400,000 deaths are attributed to HCV-related liver disease annually worldwide. Mainstay of treatment for over 25 years has been pegylated interferon until the advent of protease inhibitors, which has led to all-oral HCV treatment regimens that have changed the outlook of hepatitis C treatment. Grazoprevir/elbasvir provides high rates of efficacy and tolerability and is an all-oral once daily treatment option for HCV infection. Efficacy of grazoprevir/elbasvir has been proven in patients with cirrhosis, patients who have previously failed treatment with peginterferon and ribavirin (RBV), patients with end-stage renal disease and patients with HIV co-infection. Data have shown a high barrier to resistance despite the presence of resistance-associated substitutions. Grazoprevir/elbasvir represents a very promising regimen for treatment of HCV infection. This review provides a summary of pharmacology, efficacy, and safety of grazoprevir/elbasvir for the treatment of HCV infection. Keywords: hepatitis C virus, grazoprevir, elbasvir, NS3, NS4, NS5A, protease inhibitors Sulejmani NJafri SMDove Medical Pressarticlehepatitis c virusgrazoprevirelbasvirNS3NS4NS5Aprotease inhibitorsDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol Volume 10, Pp 33-42 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	hepatitis c virus grazoprevir elbasvir NS3 NS4 NS5A protease inhibitors Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	hepatitis c virus grazoprevir elbasvir NS3 NS4 NS5A protease inhibitors Diseases of the digestive system. Gastroenterology RC799-869 Sulejmani N Jafri SM Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
description	Nimisha Sulejmani,1 Syed-Mohammed Jafri2 1Department of Pharmacy, Henry Ford Hospital, Detroit, MI, USA; 2Division of Gastroenterology, Henry Ford Hospital, Detroit, MI, USA Abstract: Chronic hepatitis C virus (HCV) infection impacts approximately 71 million people and approximately 400,000 deaths are attributed to HCV-related liver disease annually worldwide. Mainstay of treatment for over 25 years has been pegylated interferon until the advent of protease inhibitors, which has led to all-oral HCV treatment regimens that have changed the outlook of hepatitis C treatment. Grazoprevir/elbasvir provides high rates of efficacy and tolerability and is an all-oral once daily treatment option for HCV infection. Efficacy of grazoprevir/elbasvir has been proven in patients with cirrhosis, patients who have previously failed treatment with peginterferon and ribavirin (RBV), patients with end-stage renal disease and patients with HIV co-infection. Data have shown a high barrier to resistance despite the presence of resistance-associated substitutions. Grazoprevir/elbasvir represents a very promising regimen for treatment of HCV infection. This review provides a summary of pharmacology, efficacy, and safety of grazoprevir/elbasvir for the treatment of HCV infection. Keywords: hepatitis C virus, grazoprevir, elbasvir, NS3, NS4, NS5A, protease inhibitors
format	article
author	Sulejmani N Jafri SM
author_facet	Sulejmani N Jafri SM
author_sort	Sulejmani N
title	Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
title_short	Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
title_full	Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
title_fullStr	Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
title_full_unstemmed	Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
title_sort	grazoprevir/elbasvir for the treatment of adults with chronic hepatitis c: a short review on the clinical evidence and place in therapy
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/b99cf70ffb03438d84369306678c807b
work_keys_str_mv	AT sulejmanin grazoprevirelbasvirforthetreatmentofadultswithchronichepatitiscashortreviewontheclinicalevidenceandplaceintherapy AT jafrism grazoprevirelbasvirforthetreatmentofadultswithchronichepatitiscashortreviewontheclinicalevidenceandplaceintherapy
_version_	1718400494547763200

Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy

Ejemplares similares